Cancer Res Treat 2019 Apr 16. Epub 2019 Apr 16.
Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
Purpose: Temsirolimus is effective in the treatment for metastatic non-clear cell renal cell carcinoma (nccRCC) with poor prognosis. We aim to investigate the efficacy and tolerability of temsirolimus in treatment of naïve Asian patients with metastatic/recurrent nccRCC.
Materials And Methods: From January 2008 to July 2017, data of treatment-naïve, metastatic/recurrent nccRCC patients, who were treated with temsirolimus according to the standard protocol, were collected. The primary end point was progression-free survival (PFS). Secondary end points were overall survival (OS), objective response rate (ORR), and tolerability of temsirolimus.
Results: Forty-four metastatic/recurrent nccRCC patients, 10 from prospective and 34 from retrospective groups, were enrolled; 24 patients (54%) were papillary type, and other histology subtypes included 11 (25%) chromophobe, 2 (5%) collecting duct, 1 (2%) Xp11.2 translocation, and 6 (14%) others. The median PFS and OS were 7.6 and 17.6 months, respectively. ORR was 11% and disease control rate was 83%. Patients with prior nephrectomy had longer PFS (HR 0.16; 95% confidence interval [CI], 0.06 to 0.42; p<0.001) and OS (HR, 0.15; 95% CI, 0.05 to 0.45; p<0.001). Compared to favorable/intermediate prognosis group, poor prognosis group had shorter median PFS (4.7 months vs. 7.6 months [HR, 2.91; 95% CI, 1.39 to 6.12, p=0.005] and median OS (9.2 months vs. 17.6 months [HR, 2.84; 95% CI, 1.23 to 6.56, p=0.015]).
Conclusion: Temsirolimus not only benefits poor-risk nccRCC patients, but it is also effective in favorable or intermediate risk group in Asians. Temsirolimus was well-tolerated with manageable adverse events.